Ruggiero Angelo (Angelo Ruggiero, A Ruggiero)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 134

Top Venues

Clinical, cosmetic and investigational dermatology

Clinical and experimental dermatology

Dermatologic therapy

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Matteo Megna, Ruggiero Angelo, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]. Clinical, cosmetic and investigational dermatology 17 (2024)
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, Alessia Villani, Fabrizio Martora, Ruggiero Angelo, Lucia Genco, Luca Potestio
The Past, the Present and the Future of Teledermatology: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Ruggiero Angelo, Matteo Megna
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Matteo Megna, Ruggiero Angelo, Ginevra Torta, Fabrizio Martora, Mariateresa Bianco, Luca Potestio
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced. Clinical and experimental dermatology (2024)
Matteo Megna, Ruggiero Angelo, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Antonio Portarapillo, Valeria Esposito, Matteo Megna, Luca Potestio, Rosita Comune, Fabrizio Martora, Ruggiero Angelo
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study. Clinical and experimental dermatology (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]. Clinical, cosmetic and investigational dermatology 17 (2024)
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, Alessia Villani, Fabrizio Martora, Ruggiero Angelo, Lucia Genco, Luca Potestio
The Past, the Present and the Future of Teledermatology: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Rosita Comune, Ruggiero Angelo, Antonio Portarapillo, Alessia Villani, Matteo Megna, Stefania Tamburrini, Salvatore Masala, Giacomo Sica, Fabio Sandomenico, Chandra Bortolotto, Lorenzo Preda, Mariano Scaglione
Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up. Cancers 16 (17) (2024)
Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Ruggiero Angelo, Matteo Megna
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Alessia Villani, Ruggiero Angelo, Massimiliano Scalvenzi, Matteo Megna
ChatGPT and Dermatology: friends or foes? Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Ruggiero Angelo, Matteo Megna
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clinical, cosmetic and investigational dermatology 16 (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Matteo Megna, Teresa Battista, Matteo Noto, Vincenzo Picone, Gabriella Fabbrocini, Ruggiero Angelo, Lucia Genco
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Ruggiero Angelo, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune, Matteo Megna
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert opinion on drug safety (2023)
Ruggiero Angelo, Matteo Megna, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunologic research (2023)
Matteo Megna, Teresa Battista, Matteo Noto, Vincenzo Picone, Gabriella Fabbrocini, Ruggiero Angelo, Lucia Genco
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Fabrizio Martora, Alessia Villani, Matteo Megna, Ruggiero Angelo
Comment on: "Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination" by Gambichler. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Matteo Megna, Ruggiero Angelo, Antonia Salsano, Giuseppe Lauletta, Antonio Portarapillo, Ginevra Torta, Fabrizio Martora, Luca Potestio
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab. Clinical, cosmetic and investigational dermatology 16 (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Matteo Megna, Luca Potestio, Ruggiero Angelo, Sara Cacciapuoti, Francesco Maione, Marco Tasso, Francesco Caso, Luisa Costa
JAK Inhibitors in Psoriatic Disease. Clinical, cosmetic and investigational dermatology 16 (2023)
Ruggiero Angelo, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Ruggiero Angelo, Gabriella Fabbrocini, Fabrizio Martora, Luca Costanzo, Lucia Gallo
Reply to "oral ivermectin to treat scabies: a comparison of two different regimens". Clinical and experimental dermatology (2023)
Luca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, Fabrizio Martora, Ruggiero Angelo, Matteo Megna
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al. The Australasian journal of dermatology (2023)
Fabrizio Martora, Ruggiero Angelo, Teresa Battista, Luca Potestio, Matteo Megna
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." Clinical and experimental dermatology (2023)
Luca Potestio, Teresa Battista, Sara Cacciapuoti, Ruggiero Angelo, Fabrizio Martora, Luigi Fornaro, Elisa Camela, Matteo Megna
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge. Biomedicines 11 (8) (2023)
Ruggiero Angelo, Antonio Portarapillo, Matteo Megna, Cataldo Patruno, Maddalena Napolitano
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics. Pediatric health, medicine and therapeutics 14 (2023)
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al. The Australasian journal of dermatology 64 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Ruggiero Angelo, Matteo Megna, Giuseppina Caiazzo, Melania Parisi, Massimo Mascolo, Daniela Russo, Lucia Gallo, Gabriella Fabbrocini, Maddalena Napolitano, Cataldo Patruno
Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?' Clinical and experimental dermatology 48 (4) (2023)
Ruggiero Angelo, Matteo Megna, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunologic research (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Ruggiero Angelo, Fabrizio Martora, Teresa Battista, Matteo Megna
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, Fabrizio Martora, Ruggiero Angelo, Matteo Megna
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection. Clinical, cosmetic and investigational dermatology 16 (2023)
Lidia Sacchelli, Federica Filippi, Anna Balato, Riccardo Balestri, Francesco Bellinato, Nicoletta Bernardini, L Bianchi, Martina Burlando, Campanati Anna, Marco Adriano Chessa, M Corazza, Antonella Di Cesare, V Di Lernia, F Diotallevi, Maria Esposito, Maria-Concetta Fargnoli, Paolo Gisondi, Alessandro Giunta, Katharina Hansel, Michela Magnano, Matteo Megna, Giulia Odorici, Francesca Prignano, C Potenza, G Rech, M Rovesti, Ruggiero Angelo, F Satolli, Luca Stingeni, Dino Gibertoni, F Bardazzi
PsoBioVax: A multicentric Italian case-control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapy. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Maddalena Napolitano, Ruggiero Angelo, Cataldo Patruno
Dupilumab associated inflammatory arthritis: a literature review. Clinical and experimental dermatology (2023)
Ruggiero Angelo, Claudio Marasca, Gabriella Fabbrocini, Massimo Mascolo, Vincenzo Greco
A unilateral slow-growing yellow nodule of the glans penis. Clinical and experimental dermatology 48 (1) (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Ruggiero Angelo, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of clinical medicine 12 (9) (2023)
Matteo Megna, Elisa Camela, Ruggiero Angelo, Teresa Battista, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Dalbavancin for the treatment of severe hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al. The Australasian journal of dermatology 64 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Ruggiero Angelo, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, cosmetic and investigational dermatology 16 (2023)
Matteo Megna, Ruggiero Angelo, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of clinical medicine 12 (9) (2023)
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, Gabriella Fabbrocini, Massimiliano Scalvenzi, Ruggiero Angelo, Giuseppina Caiazzo, Matteo Megna
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al. The Australasian journal of dermatology 64 (1) (2023)
Fabrizio Martora, Teresa Battista, Ruggiero Angelo, Massimiliano Scalvenzi, Alessia Villani, Matteo Megna, Luca Potestio
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature. Viruses 15 (7) (2023)
Fabrizio Martora, Claudio Marasca, Teresa Battista, Gabriella Fabbrocini, Ruggiero Angelo
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'. Clinical and experimental dermatology 47 (11) (2022)
Ruggiero Angelo, Matteo Megna, Gabriella Fabbrocini, Fabrizio Martora
Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clinical and experimental dermatology 47 (10) (2022)
Ruggiero Angelo, Fabrizio Martora, Luigi Fornaro, Gianluca Guerrasio, Francesca di Vico, Gabriella Fabbrocini, Massimiliano Scalvenzi, Alessia Villani
The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre. Clinical and experimental dermatology 47 (11) (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety (2022)
Fabrizio Martora, Ruggiero Angelo, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to 'Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review' by Pauluzzi et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Orlando Zagaria, Alessia Villani, Ruggiero Angelo, Luca Potestio, Gabriella Fabbrocini, Lucia Gallo
New-onset lichen planus arising after COVID-19 vaccination. Dermatologic therapy 35 (5) (2022)
Fabrizio Martora, Teresa Battista, Ruggiero Angelo, Gabriella Fabbrocini, Luca Potestio
Comment on 'Morphoea following COVID-19 vaccination'. Clinical and experimental dermatology 47 (12) (2022)
Ruggiero Angelo, Claudio Marasca, Alessia Villani, Gabriella Fabbrocini, Fabrizio Martora
Tacrolimus ointment may improve the effectiveness of adalimumab in patients with hidradenitis suppurativa: a novel promising treatment. Clinical and experimental dermatology 47 (10) (2022)
Ruggiero Angelo, Fabrizio Martora, Gabriella Fabbrocini, Alessia Villani, Claudio Marasca, Matteo Megna, Luigi Fornaro, Rosita Comune, Luca Potestio
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review. Clinical, cosmetic and investigational dermatology 15 (2022)
Fabrizio Martora, Ruggiero Angelo, Gabriella Fabbrocini, Alessia Villani
Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on 'A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK's first wave of the COVID-19 pandemic in a single, secondary-care dermatology department'. Clinical and experimental dermatology 47 (11) (2022)
Ruggiero Angelo, Claudio Marasca, Gabriella Fabbrocini, Alessia Villani, Fabrizio Martora
Teledermatology in the management of hidradenitis suppurativa: Should we improve this service? Journal of cosmetic dermatology (2022)
Matteo Megna, Elisa Camela, Ruggiero Angelo, Gabriella Fabbrocini, Luca Potestio
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al. International journal of dermatology 61 (10) (2022)
Ruggiero Angelo, Matteo Megna, Gabriella Fabbrocini, Luigi Fornaro, Alessia Villani
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety 21 (10) (2022)
Ruggiero Angelo, Matteo Megna, Alessia Villani, Rosita Comune, Gabriella Fabbrocini, Francesca di Vico
Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment. Clinical, cosmetic and investigational dermatology 15 (2022)
Ruggiero Angelo, Fabrizio Martora, Vincenzo Picone, Laura Marano, Gabriella Fabbrocini, Claudio Marasca
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. Biomedicines 10 (2) (2022)
Ruggiero Angelo, Mariateresa Nocerino, Giovanni Trischitta, Luca Costanzo, Gabriella Fabbrocini, Lucia Gallo, Matteo Megna
Persistent candidiasis infection during anti-IL-17 treatment for plaque psoriasis requiring biologic discontinuation: a case series and literature review. International journal of dermatology (2022)
Fabrizio Martora, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?' Clinical and experimental dermatology 47 (10) (2022)
Ruggiero Angelo, Luca Potestio, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Reply to 'Nail psoriasis: A rare mRNA COVID-19 vaccine reaction' by Lamberti A et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Ruggiero Angelo, Fabrizio Martora, Vincenzo Picone, Luca Potestio, Elisa Camela, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clinical and experimental dermatology 47 (12) (2022)
Matteo Megna, Teresa Battista, Luca Potestio, Ruggiero Angelo, Virginia Ventura, Gabriella Fabbrocini, Vincenzo Picone
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. Journal of cosmetic dermatology (2022)
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Ruggiero Angelo
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. Psoriasis (Auckland, N.Z.) 12 (2022)
Ruggiero Angelo, Matteo Megna, Vincenzo Marino, Luca Costanzo, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza, Chiara Miano, Lucia Gallo
A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued? Dermatologic therapy 35 (4) (2022)
Ruggiero Angelo, Alessia Villani, Gabriella Fabbrocini, Fabrizio Martora
Reply to: "Usage and perceptions of teledermatology in 2021: a survey of dermatologists" by Ahmad et al. International journal of dermatology (2022)
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Ruggiero Angelo
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. Dermatologic therapy 35 (9) (2022)
Fabrizio Martora, Gabriella Fabbrocini, Lucia Gallo, Ruggiero Angelo
Comment on 'Unexpected consequences of SARS-CoV-2 pandemic: scabies infestation'. Clinical and experimental dermatology 47 (10) (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety 21 (12) (2022)
Elisa Camela, Luca Potestio, Ruggiero Angelo, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Matteo Megna
Towards Personalized Medicine in Psoriasis: Current Progress. Psoriasis (Auckland, N.Z.) 12 (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety (2022)
Luca Potestio, Lucia Genco, Alessia Villani, Claudio Marasca, G Fabbrocini, L Fornaro, Ruggiero Angelo, Fabrizio Martora
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (11) (2022)
Ruggiero Angelo, Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Matteo Megna
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckland, N.Z.) 12 (2022)
Ruggiero Angelo, Matteo Megna, Giuseppina Caiazzo, Melania Parisi, Massimo Mascolo, Daniela Russo, Lucia Gallo, Gabriella Fabbrocini, Maddalena Napolitano, Cataldo Patruno
Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?' Clinical and experimental dermatology (2022)
Matteo Megna, Luca Potestio, Ruggiero Angelo, Elisa Camela, Gabriella Fabbrocini
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Dermatologic therapy 35 (7) (2022)
Ruggiero Angelo, Fabrizio Martora, Gabriella Fabbrocini, Alessia Villani, Claudio Marasca, Matteo Megna, Luigi Fornaro, Rosita Comune, Luca Potestio
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review. Clinical, cosmetic and investigational dermatology 15 (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety 21 (12) (2022)
Ruggiero Angelo, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clinical, cosmetic and investigational dermatology 15 (2022)
Ruggiero Angelo, Luca Potestio, Sara Cacciapuoti, Lucia Gallo, Teresa Battista, Elisa Camela, Gabriella Fabbrocini, Matteo Megna
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study. Dermatologic therapy (2022)

Ruggiero Angelo.css-eqlu8i{font-size:small;padding-left:4px;} (Angelo Ruggiero, A Ruggiero)

Publication Activity (10 Years)

Top Topics

Top Venues

Ruggiero Angelo (Angelo Ruggiero, A Ruggiero)